Twist Bioscience (NASDAQ:TWST) Trading 8% Higher

Twist Bioscience Co. (NASDAQ:TWST) traded up 8% during mid-day trading on Tuesday . The stock traded as high as $31.81 and last traded at $31.81. 105,794 shares were traded during trading, a decline of 88% from the average session volume of 907,955 shares. The stock had previously closed at $29.45.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Scotiabank upped their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research note on Monday, February 5th. Barclays dropped their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Finally, The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and upped their price objective for the company from $25.00 to $45.00 in a research note on Wednesday, January 17th.

Twist Bioscience Stock Down 2.4 %

The firm’s 50 day moving average price is $35.15 and its two-hundred day moving average price is $30.32.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The business had revenue of $71.50 million during the quarter, compared to analysts’ expectations of $67.59 million. During the same quarter in the prior year, the company posted ($0.74) EPS. The business’s revenue for the quarter was up 31.8% on a year-over-year basis. As a group, sell-side analysts forecast that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Insider Activity

In related news, Director Robert Chess sold 4,110 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the transaction, the director now owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Robert Chess sold 4,110 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the transaction, the director now owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total transaction of $37,810.56. Following the transaction, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The disclosure for this sale can be found here. Insiders sold a total of 11,037 shares of company stock valued at $384,092 in the last 90 days. Company insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the business. Federated Hermes Inc. acquired a new stake in Twist Bioscience during the 3rd quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. lifted its holdings in Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock worth $30,000 after buying an additional 721 shares in the last quarter. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the 4th quarter worth approximately $30,000. Allspring Global Investments Holdings LLC lifted its holdings in Twist Bioscience by 51.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock worth $70,000 after buying an additional 1,179 shares in the last quarter. Finally, International Assets Investment Management LLC raised its holdings in shares of Twist Bioscience by 3,519.8% in the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after purchasing an additional 3,907 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.